ROUSES POINT - Akrimax Pharmaceuticals has signed a major contract which is expected to bring work to its facility in the village of Rouses Point.
In announcement released by Akrimax Dec. 29, the corporation stated a manufacturing agreement for the production of pharmaceutical products for a global company will begin in 2009. Akrimax was reportedly selected from several potential partners in a competitive process for the contract, from the unnamed manufacturer.
Akrimax president Alan L. Rubino issued a statement in which he said the agreement "further validates Akrimax's decision to acquire the Rouses Point facility which possesses, diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record."
"We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility," he stated. "Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility."
Rubino further stated the company is "proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA."
Timothy Soule, Akrimax vice president of human resources and government affairs, said his corporation could not disclose further details of the contract, including the name of manufacturer and the length and other terms of the agreement, but said it was a "significant win" for Akrimax.
"We felt it was important to let the people of the North Country know about this agreement. We're very pleased," said Soule.
The news came as a pleasant surprise to Garry F. Douglas, president of the Plattsburgh-North Country Chamber of Commerce.
Douglas and the chamber of commerce have been credited for playing a pivotal role in bringing Akrimax to the village following the 2006 announcement by Wyeth Pharmaceuticals it would cease operations at its drug product manufacturing and packaging plant. Almost immediately following the announcement, the chamber of commerce began working with local and state agencies to find a new employer to take the place of Wyeth, which it successfully announced with Akrimax's acquisition of the facility last January.
"Akrimax is committed to transitioning the Rouses Point operation to a combination of Akrimax branded products and contract manufacturing, and this confirms that they are on track," Douglas said in a prepared statement. "While we may have further bumps in the coming months, we have good reason to be confident about the future of pharmaceutical manufacturing in the North Country, and we are continuing to work actively with Akrimax on other exciting opportunities."
When reached for comment, Village Mayor George A. Rivers said he hadn't heard anything about the agreement secured by Akrimax but said the news sounded favorable for the village.
"Anytime you have anything coming into that facility, it's good news because that means people will be working," said Rivers.
Akrimax and Wyeth are working under a cooperative relationship during the transition at the Rouses Point facility, which will conclude at the end of 2009. Akrimax is leasing the facility to Wyeth while the company continues to manufacture its products and Akrimax integrates its own products into the facility.